The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.

Esperantra, a non-profit organization working to reduce cancer mortality in Peru, has generously agreed to partner with The Max Foundation to facilitate the importation of medicines within Max Access Solutions.

“Esperantra and The Max Foundation are a perfect fit together,” said Inés García González, The Max Foundation’s Region Head for Latin America. “Our organizations have similar goals – expanding access to treatment, reducing cancer mortality, etc. – and Esperantra is a well-established organization in Peru with a great track record. We are honored to partner with them.”

Karla Ruiz de Castilla, Esperantra’s Executive Director, said: “It is our pleasure to partner with The Max Foundation and help expand access to treatment for patients in Peru. Together we are improving clinical outcomes and quality of life for people facing cancer.”

Thanks to the partnership with Esperantra, Peru has become the 70th country to have patients enrolled in Max Access Solutions.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….

  • The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation Renews and Expands Agreement with Incyte

    The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.

  • The Max Foundation and Tanner Pharma partner on innovative drug distribution model

    The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.